Oclacitinib (APOQUEL®) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy

Journal of Veterinary Pharmacology and Therapeutics

Volumn 37, Issue 4, 2014, Pages 317-324

  Gonzales, A J ^a   Bowman, J W ^a   Fici, G J ^a   Zhang, M ^b   Mann, D W ^b   Mitton Fry, M ^c  

^a ZOETIS   (United States)

^b PFIZER INC   (United States)

^c OHIO WESLEYAN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 23; INTERLEUKIN 4; INTERLEUKIN 6; JANUS KINASE; JANUS KINASE 1; OCLACITINIB; CYTOKINE; DERMATOLOGICAL AGENT; ENZYME; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

ANIMAL CELL; ARTICLE; DOG DISEASE; DRUG POTENCY; DRUG SELECTIVITY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PRURITUS; SKIN ALLERGY; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; CHEMICAL STRUCTURE; CHEMISTRY; DOG; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM;

CANIS FAMILIARIS;

ANIMALS; CYTOKINES; DERMATOLOGIC AGENTS; DOGS; ENZYMES; GENE EXPRESSION REGULATION; HUMANS; JANUS KINASES; MOLECULAR STRUCTURE; PYRIMIDINES; SULFONAMIDES;

EID: 84903820508     PISSN: 01407783     EISSN: 13652885     Source Type: Journal    
DOI: 10.1111/jvp.12101     Document Type: Article

References (18)

1. Brandt, E.B. & Sivaprasad, U. (2011) Th2 cytokines and atopic dermatitis. Journal of Clinical and Cellular Immunology, 2, 1-25.
2. Carmi-Levy, I., Homey, B. & Soumelis, V. (2011) A modular view of cytokine networks in atopic dermatitis. Clinical Reviews in Allergy and Immunology, 41, 245-253.
3. Cosgrove, S.B., Wren, J.A., Cleaver, D.M., Martin, D.D., Walsh, K.F., Harfst, J.A., Follis, S.L., King, V.L., Boucher, J.F. & Stegemann, M.R. (2013) Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis. Veterinary Dermatology, 24, 479-487.
4. Dillon, S.R., Sprecher, C., Hammond, A., Bilsborough, J., Rosenfeld-Franklin, M., Presnell, S.R., Haugen, H.S., Maurer, M., Harder, B., Johnston, J., Bort, S., Mudri, S., Kuijper, J.L., Bukowski, T., Shea, P., Dong, D.L., Dasovich, M., Grant, F.J., Lockwood, L., Levin, S.D., LeCiel, C., Waggie, K., Day, H., Topouzis, S., Kramer, J., Kuestner, R., Chen, Z., Foster, D., Parrish-Novak, J. & Gross, J.A. (2004) Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nature Immunology, 5, 752-760.
5. Gonzales, A.J., Humphrey, W.R., Messamore, J.E., Fleck, T.J., Fici, G.J., Shelly, J.A., Teel, J.F., Bammert, G.F., Dunham, S.A., Fuller, T.E. & McCall, R.B. (2013) Interleukin-31: its role in canine pruritus and naturally occurring canine atopic dermatitis. Veterinary Dermatology, 24, 48-53. e11-e42.
6. Harrison, D.A. (2012) The Jak/STAT pathway. Cold Spring Harbor Perspectives in Biology, 4, 1-3.
7. Izuhara, K., Arima, K. & Yasunaga, S. (2002) IL-4 and IL-13: their pathological roles in allergic diseases and their potential in developing new therapies. Current Drug Targets: Inflammation & Allergy, 1, 263-269.
8. Marsella, R., Olivry, T. & Maeda, S. (2006) Cellular and cytokine kinetics after epicutaneous allergen challenge (atopy patch testing) with house dust mites in high-IgE beagles. Veterinary Dermatology, 17, 111-120.
9. Menet, C.J., Rompaey, L.V. & Geney, R. (2013) Advances in the discovery of selective JAK inhibitors. Progress in Medicinal Chemistry, 52, 153-223.
10. Meyer, D.M., Jesson, M.I., Li, X., Elrick, M.M., Funckes-Shippy, C.L., Warner, J.D., Gross, C.J., Dowty, M.E., Ramaiah, S.K., Hirsch, J.L., Saabye, M.J., Barks, J.L., Kishore, N. & Morris, D.L. (2010) Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690, 550, in rat adjuvant-induced arthritis. Journal of Inflammation, 7, 41.
11. Mihara, M., Hashizume, M., Yoshida, H., Suzuki, M. & Shiina, M. (2012) IL-6/IL-6 receptor system and its role in physiological and pathological conditions. Clinical Science, 122, 143-159.
12. Nuttall, T.J., Knight, P.A., McAleese, S.M., Lamb, J.R. & Hill, P.B. (2002) Expression of Th1, Th2 and immunosuppressive cytokine gene transcripts in canine atopic dermatitis. Clinical and Experimental Allergy, 32, 789-795.
13. Olivry, T., Dean, G.A., Tompkins, M.B., Dow, J.L. & Moore, P.F. (1999) Toward a canine model of atopic dermatitis: amplification of cytokine-gene transcripts in the skin of atopic dogs. Experimental Dermatology, 8, 204-211.
14. Ong, P.Y. & Leung, D.Y. (2006) Immune dysregulation in atopic dermatitis. Current Allergy and Asthma Reports, 6, 384-389.
15. Schindler, C. & Plumlee, C. (2008) Interferons pen the JAK-STAT pathway. Seminars in Cell & Developmental Biology, 19, 311-318.
16. Schlotter, Y.M., Rutten, V.P., Riemers, F.M., Knol, E.F. & Willemse, T. (2011) Lesional skin in atopic dogs shows a mixed Type-1 and Type-2 immune responsiveness. Veterinary Immunology and Immunopathology, 143, 20-26.
17. Vignali, D.A. & Kuchroo, V.K. (2012) IL-12 family cytokines: immunological playmakers. Nature Immunology, 13, 722-728.
18. Wills-Karp, M. & Finkelman, F.D. (2008) Untangling the complex web of IL-4- and IL-13-mediated signaling pathways. Sci Signal, 1, 1-4.